Angsana Phuphuakrat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Angsana Phuphuakrat has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Ekawat Pasomsub
Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
7 shared publications- Somnuek Sungkanuparph
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
7 shared publications Sirawat Srichatrapimuk
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University
6 shared publicationsSomnuek Sungkanuparph
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
6 shared publicationsSasisopin Kiertiburanakul
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
5 shared publications- Arkom Nongnuch
Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 27  (1)
Electrocardiograms and screening echocardiograms in young adults who acquired HIV perinatally and non-perinatally: a pilot study
Human immunodeficiency virus (HIV) targets the immune system primarily by destroying CD4+ T lymphocytes. Left untreated, HIV infection leads to acquired immunodeficiency syndrome (AIDS). While the ...
- 16 October 2026
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 27  (1)
Open AccessElectrocardiograms and screening echocardiograms in young adults who acquired HIV perinatally and non-perinatally: a pilot study
Human immunodeficiency virus (HIV) targets the immune system primarily by destroying CD4+ T lymphocytes. Left untreated, HIV infection leads to acquired immunodeficiency syndrome (AIDS). While the ...
- Open Access
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14  (10)
Diagnostic yield and impact of internal transcribed spacer sequencing from clinical specimens on antifungal management in patients with suspected fungal infection
Internal transcribed spacer (ITS) sequencing has been increasingly used for the diagnosis of fungal infection. However, data on its real-world clinical utility are limited. We retrospectively evaluated the diagnostic yield from direct clinical specimens using the final diagnosis as the gold standard, and studied the impact of ITS sequencing on antifungal management in a university hospital with an unrestricted order setting. A total of 315 specimens were collected from 227 patients between November 2023 and April 2024. Of these, 59 (18.7%) were from fungal infection cases. ITS sequencing demonstrated a sensitivity of 35.6% and specificity of 96.9%. Agreement with fungal culture was 79.7% (κ = 0.583). In our setting, the median turnaround time of the positive results was 12 (12–14) days. ITS sequencing altered clinical management in only 2 patients (0.9%). The culture-negative but ITS sequencing-positive specimens mostly represented colonizers from bronchoalveolar lavage fluid. In an unrestricted setting, ITS sequencing showed low sensitivity and minimal impact on clinical decision-making. To maximize diagnostic benefit and utility, implementation of diagnostic stewardship is necessary. IMPORTANCE: This study provides a real-life evaluation of internal transcribed spacer (ITS) sequencing in an unrestricted clinical setting. We demonstrated fair sensitivity and minimal impact on antifungal alteration. We identified critical implementation barriers, including prolonged turnaround times and the frequent detection of colonizers, which fail to guide acute decision-making. These findings are vital for informing hospital policy and advocating for strict diagnostic stewardship to maximize clinical benefit.
- 6 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14  (10)
Open AccessDiagnostic yield and impact of internal transcribed spacer sequencing from clinical specimens on antifungal management in patients with suspected fungal infection
Internal transcribed spacer (ITS) sequencing has been increasingly used for the diagnosis of fungal infection. However, data on its real-world clinical utility are limited. We retrospectively evaluated the diagnostic yield from direct clinical specimens using the final diagnosis as the gold standard, and studied the impact of ITS sequencing on antifungal management in a university hospital with an unrestricted order setting. A total of 315 specimens were collected from 227 patients between November 2023 and April 2024. Of these, 59 (18.7%) were from fungal infection cases. ITS sequencing demonstrated a sensitivity of 35.6% and specificity of 96.9%. Agreement with fungal culture was 79.7% (κ = 0.583). In our setting, the median turnaround time of the positive results was 12 (12–14) days. ITS sequencing altered clinical management in only 2 patients (0.9%). The culture-negative but ITS sequencing-positive specimens mostly represented colonizers from bronchoalveolar lavage fluid. In an unrestricted setting, ITS sequencing showed low sensitivity and minimal impact on clinical decision-making. To maximize diagnostic benefit and utility, implementation of diagnostic stewardship is necessary. IMPORTANCE: This study provides a real-life evaluation of internal transcribed spacer (ITS) sequencing in an unrestricted clinical setting. We demonstrated fair sensitivity and minimal impact on antifungal alteration. We identified critical implementation barriers, including prolonged turnaround times and the frequent detection of colonizers, which fail to guide acute decision-making. These findings are vital for informing hospital policy and advocating for strict diagnostic stewardship to maximize clinical benefit.
- Open Access
- 9 June 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23  (1) , 1-9
Diagnostic stewardship to limit repeat plasma cytomegalovirus viral load testing
Background: Frequent serial monitoring of plasma cytomegalovirus (CMV) viral load caused unnecessary budgets for laboratory testing without changes in treatment. We aimed to implement diagnostic stewardship to limit CMV viral load testing at appropriate intervals. Methods: A quasi-experimental study was performed. To avoid unnecessary plasma CMV viral load testing, the inpatient electronic pop-up reminder was launched in 2021. In cases with plasma CMV viral load testing was ordered in intervals of less than five days, telephone interview and feedback were performed. Pre-post intervention data was compared in terms of clinical and monetary outcomes. The rate of plasma CMV viral load testing performed in intervals of less than five days was compared between 2021 and 2019 using the Poisson regression model. Results: After the protocol implementation, there was a significant decrease in the rate of plasma CMV viral load test orders in intervals of less than five days from 17.5% to 8.0% [incidence rate ratio 0.40, p < 0.001]. There was no statistically significant difference in the incidence of CMV DNAemia and CMV disease (p = 0.407 and 0.602, respectively). As a result, the hospital could save the costs of plasma CMV viral load testing per 1,000 patients performed with intervals of less than five days from 2,646,048.11 to 1,360,062.89 Thai Baht. Conclusions: The diagnostic stewardship program is safe and helpful in reducing unnecessary plasma CMV viral load testing and costs.
- 9 June 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23  (1) , 1-9
Open AccessDiagnostic stewardship to limit repeat plasma cytomegalovirus viral load testing
Background: Frequent serial monitoring of plasma cytomegalovirus (CMV) viral load caused unnecessary budgets for laboratory testing without changes in treatment. We aimed to implement diagnostic stewardship to limit CMV viral load testing at appropriate intervals. Methods: A quasi-experimental study was performed. To avoid unnecessary plasma CMV viral load testing, the inpatient electronic pop-up reminder was launched in 2021. In cases with plasma CMV viral load testing was ordered in intervals of less than five days, telephone interview and feedback were performed. Pre-post intervention data was compared in terms of clinical and monetary outcomes. The rate of plasma CMV viral load testing performed in intervals of less than five days was compared between 2021 and 2019 using the Poisson regression model. Results: After the protocol implementation, there was a significant decrease in the rate of plasma CMV viral load test orders in intervals of less than five days from 17.5% to 8.0% [incidence rate ratio 0.40, p < 0.001]. There was no statistically significant difference in the incidence of CMV DNAemia and CMV disease (p = 0.407 and 0.602, respectively). As a result, the hospital could save the costs of plasma CMV viral load testing per 1,000 patients performed with intervals of less than five days from 2,646,048.11 to 1,360,062.89 Thai Baht. Conclusions: The diagnostic stewardship program is safe and helpful in reducing unnecessary plasma CMV viral load testing and costs.
- Open Access
- 13 March 2023
- Published by Elsevier in Public Health in Practice
- Vol. 5, 100378
Saliva and wastewater surveillance for SARS-CoV-2 during school reopening amid COVID-19 pandemic in Thailand
- 13 March 2023
- Published by Elsevier in Public Health in Practice
- Vol. 5, 100378
Open AccessSaliva and wastewater surveillance for SARS-CoV-2 during school reopening amid COVID-19 pandemic in Thailand
- Open Access
- 27 February 2023
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 20  (1) , 1-8
Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
Background: Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We studied the effect of pitavastatin on atherosclerotic-associated inflammatory biomarkers in PLHIV receiving ART. Methods: A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir/ritonavir (ATV/r) to evaluate the effect of 2 mg/day pitavastatin treatment versus placebo. High-sensitivity CRP (hs-CRP), cytokines, and cellular markers in PLHIV receiving 12 weeks of pitavastatin or placebo were investigated. Results: A total of 24 HIV-infected individuals with a median (interquartile range) age of 46 (41–54) years were recruited, and the median CD4 T cell count was 662 (559-827) cells/mm3. The median duration of ATV/r use was 36 (24–48) months. Significant change in levels of basic fibroblast growth factor (FGF) between pitavastatin treatment and placebo at week 12 from baseline was observed (27.1 vs. 20.5 pg/mL; p=0.023). However, there were no significant changes from baseline of hs-CRP and other plasma cytokine levels at week 12 of pitavastatin or placebo. Regarding cellular markers, percentages of HLA-DR+CD38-CD4+ T cells and PD1+CD4+ T cells significantly decreased from baseline in PLHIV receiving pitavastatin for 12 weeks, as compared to placebo (− 0.27 vs. 0.02%; p=0.049 and − 0.23 vs. 0.23%; p=0.022, respectively). Conclusions: Pitavastatin treatment increases basic FGF levels, and lowers HLA-DR+CD38-CD4+ T cells, and PD1+CD4+ T cells. Further study on the effects of pitavastatin on preventing cardiovascular diseases in PLHIV should be pursued.
- 27 February 2023
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 20  (1) , 1-8
Open AccessEffects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
Background: Chronic inflammation has been described in people living with HIV (PLHIV) receiving antiretroviral therapy (ART) despite viral suppression. Inflammation associated non-communicable diseases, including atherosclerosis, are becoming recognized complication of HIV infection. We studied the effect of pitavastatin on atherosclerotic-associated inflammatory biomarkers in PLHIV receiving ART. Methods: A randomized, double-blind, crossover study was conducted in HIV-infected persons with dyslipidemia and receiving atazanavir/ritonavir (ATV/r) to evaluate the effect of 2 mg/day pitavastatin treatment versus placebo. High-sensitivity CRP (hs-CRP), cytokines, and cellular markers in PLHIV receiving 12 weeks of pitavastatin or placebo were investigated. Results: A total of 24 HIV-infected individuals with a median (interquartile range) age of 46 (41–54) years were recruited, and the median CD4 T cell count was 662 (559-827) cells/mm3. The median duration of ATV/r use was 36 (24–48) months. Significant change in levels of basic fibroblast growth factor (FGF) between pitavastatin treatment and placebo at week 12 from baseline was observed (27.1 vs. 20.5 pg/mL; p=0.023). However, there were no significant changes from baseline of hs-CRP and other plasma cytokine levels at week 12 of pitavastatin or placebo. Regarding cellular markers, percentages of HLA-DR+CD38-CD4+ T cells and PD1+CD4+ T cells significantly decreased from baseline in PLHIV receiving pitavastatin for 12 weeks, as compared to placebo (− 0.27 vs. 0.02%; p=0.049 and − 0.23 vs. 0.23%; p=0.022, respectively). Conclusions: Pitavastatin treatment increases basic FGF levels, and lowers HLA-DR+CD38-CD4+ T cells, and PD1+CD4+ T cells. Further study on the effects of pitavastatin on preventing cardiovascular diseases in PLHIV should be pursued.
- Open Access
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10  (6) , e0209422
Diagnostic Yield and Impact on Antimicrobial Management of 16S rRNA Testing of Clinical Specimens
16S rRNA gene sequencing has been increasingly used in clinical practice. Using the final diagnosis as a gold standard, the sensitivity of 16S rRNA gene sequencing was fair. In the setting with no 16S rRNA gene sequencing test ordering restrictions, only small percentages of the test results had an impact on antimicrobial management. Restrictions on test requests should be developed to maximize the benefit of the test.
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10  (6) , e0209422
Open AccessDiagnostic Yield and Impact on Antimicrobial Management of 16S rRNA Testing of Clinical Specimens
16S rRNA gene sequencing has been increasingly used in clinical practice. Using the final diagnosis as a gold standard, the sensitivity of 16S rRNA gene sequencing was fair. In the setting with no 16S rRNA gene sequencing test ordering restrictions, only small percentages of the test results had an impact on antimicrobial management. Restrictions on test requests should be developed to maximize the benefit of the test.
- Open Access
- 30 October 2022
- Published by SAGE Publications in Journal of the International Association of Providers of AIDS Care (JIAPAC)
- Vol. 21
Risk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
Tenofovir disoproxil fumarate (TDF) associates with renal tubular dysfunction (RTD) in some people living with HIV (PLWH). We studied clinical and genetic factors associated with RTD in Thai PLWH receiving TDF. RTD was diagnosed in 13 of 65 (20%) patients. The median (interquartile range) age and CD4 cell counts were 43.8 (40.4-50.9) years and 554 (437-716) cells/mm3, respectively. The median duration of TDF use was 46.9 (31.5-54.1) months. Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of ABCC4 gene as predisposing factors of RTD. In multivariate model, concomitant use of PI [adjusted odds ratio (aOR) 11.39; 95% confidence interval (CI), 1.59- 81.56; P = 0.015], hyperlipidemia (aOR 8.59; 95% CI, 1.46-50.40; P = 0.017), and BMI (aOR 0.76; 95% CI, 0.59-0.98; P = 0.037) remained associated with RTD in patients receiving TDF. PLWH receiving TDF with the presence of these factors should be closely monitored for RTD.
- 30 October 2022
- Published by SAGE Publications in Journal of the International Association of Providers of AIDS Care (JIAPAC)
- Vol. 21
Open AccessRisk Factors of Renal Tubular Dysfunction in Thai People Living with HIV Receiving Tenofovir Disoproxil Fumarate
Tenofovir disoproxil fumarate (TDF) associates with renal tubular dysfunction (RTD) in some people living with HIV (PLWH). We studied clinical and genetic factors associated with RTD in Thai PLWH receiving TDF. RTD was diagnosed in 13 of 65 (20%) patients. The median (interquartile range) age and CD4 cell counts were 43.8 (40.4-50.9) years and 554 (437-716) cells/mm3, respectively. The median duration of TDF use was 46.9 (31.5-54.1) months. Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of ABCC4 gene as predisposing factors of RTD. In multivariate model, concomitant use of PI [adjusted odds ratio (aOR) 11.39; 95% confidence interval (CI), 1.59- 81.56; P = 0.015], hyperlipidemia (aOR 8.59; 95% CI, 1.46-50.40; P = 0.017), and BMI (aOR 0.76; 95% CI, 0.59-0.98; P = 0.037) remained associated with RTD in patients receiving TDF. PLWH receiving TDF with the presence of these factors should be closely monitored for RTD.
- Open Access
- 29 July 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2  (7) , e0000842
Missed opportunities for earlier diagnosis of HIV infection in people living with HIV in Thailand
HIV testing is the first step to making people living with HIV (PLHIV) aware of their status. Thailand is among the countries where antiretroviral therapy is initiated in PLHIV at the lowest CD4 cell counts. We aimed to quantify and characterize missed opportunity (MO) for earlier diagnosis of HIV infection in PLHIV in Thailand. The medical records of adults who were newly diagnosed with HIV between 2019 and 2020 at the two tertiary hospitals in Thailand were reviewed. A hospital visit due to an HIV clinical indicator disease but an HIV test was not performed was considered an MO for HIV testing. Of 422 newly diagnosed PLHIV, 60 persons (14.2%) presented with at least one MO, and 20 persons (33.3%) had more than one MO. In PLHIV with MO, the median (interquartile range) time between the first MO event and HIV diagnosis was 33.5 (7–166) days. The three most common clinical manifestations that were missed were skin manifestations (25.0%), unexplained weight loss (15.7%), and unexplained lymphadenopathy (14.3%). Anemia was a factor associated with MO for HIV diagnosis [odds ratio (OR) 2.24, 95% confidence interval (CI) 1.25–4.35; p = 0.018]. HIV screening reduced the risk of MO for HIV diagnosis (OR 0.53 95% CI 0.29–0.95; p = 0.032). In conclusion, MOs for earlier diagnosis of HIV infection occurred in both participating hospitals in Thailand. Skin manifestations were the most common clinical indicator diseases that were missed. HIV testing should be offered for patients with unexplained anemia. Campaigns for HIV screening tests should be promoted.
- 29 July 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2  (7) , e0000842
Open AccessMissed opportunities for earlier diagnosis of HIV infection in people living with HIV in Thailand
HIV testing is the first step to making people living with HIV (PLHIV) aware of their status. Thailand is among the countries where antiretroviral therapy is initiated in PLHIV at the lowest CD4 cell counts. We aimed to quantify and characterize missed opportunity (MO) for earlier diagnosis of HIV infection in PLHIV in Thailand. The medical records of adults who were newly diagnosed with HIV between 2019 and 2020 at the two tertiary hospitals in Thailand were reviewed. A hospital visit due to an HIV clinical indicator disease but an HIV test was not performed was considered an MO for HIV testing. Of 422 newly diagnosed PLHIV, 60 persons (14.2%) presented with at least one MO, and 20 persons (33.3%) had more than one MO. In PLHIV with MO, the median (interquartile range) time between the first MO event and HIV diagnosis was 33.5 (7–166) days. The three most common clinical manifestations that were missed were skin manifestations (25.0%), unexplained weight loss (15.7%), and unexplained lymphadenopathy (14.3%). Anemia was a factor associated with MO for HIV diagnosis [odds ratio (OR) 2.24, 95% confidence interval (CI) 1.25–4.35; p = 0.018]. HIV screening reduced the risk of MO for HIV diagnosis (OR 0.53 95% CI 0.29–0.95; p = 0.032). In conclusion, MOs for earlier diagnosis of HIV infection occurred in both participating hospitals in Thailand. Skin manifestations were the most common clinical indicator diseases that were missed. HIV testing should be offered for patients with unexplained anemia. Campaigns for HIV screening tests should be promoted.
- Open Access
Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD), 28 peritoneal dialyzed (PD) patients, and 14 healthy controls. Participants received two doses of inactivated SARS-CoV-2 vaccine followed by a dose of ChAdOx1 nCoV-19 vaccine. At 6 months, median anti-RBD IgG titers (IQR) significantly declined from baseline in the HD (1741 (1136–3083) BAU/mL vs. 373 (188–607) BAU/mL) and PD (1093 (617–1911) BAU/mL vs. 180 (126–320) BAU/mL) groups, as did the mean percent inhibition of neutralizing antibodies (HD: 96% vs. 81%; PD: 95% vs. 73%) (all p < 0.01). Age and post-vaccination serological response intensity were predictors of early humoral seroprotection loss. In contrast, cell-mediated immunity remained unchanged. In conclusion, humoral immunity declined substantially in dialysis patients, while cell-mediated immunity remained stable 6 months after the extended heterologous primary series of two inactivated SARS-CoV-2/ChAdOx1 nCoV-19 vaccine. A booster dose could be considered in dialysis patients 3 months after this unique regimen, particularly in the elderly or those with a modest initial humoral response.
Open AccessDurability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD), 28 peritoneal dialyzed (PD) patients, and 14 healthy controls. Participants received two doses of inactivated SARS-CoV-2 vaccine followed by a dose of ChAdOx1 nCoV-19 vaccine. At 6 months, median anti-RBD IgG titers (IQR) significantly declined from baseline in the HD (1741 (1136–3083) BAU/mL vs. 373 (188–607) BAU/mL) and PD (1093 (617–1911) BAU/mL vs. 180 (126–320) BAU/mL) groups, as did the mean percent inhibition of neutralizing antibodies (HD: 96% vs. 81%; PD: 95% vs. 73%) (all p < 0.01). Age and post-vaccination serological response intensity were predictors of early humoral seroprotection loss. In contrast, cell-mediated immunity remained unchanged. In conclusion, humoral immunity declined substantially in dialysis patients, while cell-mediated immunity remained stable 6 months after the extended heterologous primary series of two inactivated SARS-CoV-2/ChAdOx1 nCoV-19 vaccine. A booster dose could be considered in dialysis patients 3 months after this unique regimen, particularly in the elderly or those with a modest initial humoral response.